Evaluation of XRCC1 Gene Polymorphism as a Biomarker in Head and Neck Cancer Patients Undergoing Chemoradiation Therapy

Nanda, Sambit Swarup; Gandhi, Ajeet Kumar; Rastogi, Madhup; Khurana, Rohini; Hadi, Rahat; Sahni, Kamal; Mishra, Shashwat; Srivastava, Anoop Kumar; Bhatt, Madan Lal Brahma; Parmar, Devendra

doi:10.1016/j.ijrobp.2018.03.039

Cited by 32 publications

(36 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…31 In head and neck cancer case-control studies, XRCC-1 Arg194Trp genotypic expression for wild varies from 37% to 89%, and for polymorphic it varies from 10% to 63%. 21,25,[32][33][34][35][36][37][38][39][40][41][42] The proportion of XRCC-1 Arg194Trp wild (42.5%) and polymorphic (57.5%) variants in our study was in accordance with the present case-control studies (Table S4), and it follows the Hardy-Weinberg principle. A majority of the patients in our cohort were from the rural area and lower socioeconomic class, where alcohol and tobacco use are common, hence pervasiveness of this substance use was seen higher.…”

Section: Discussionsupporting

confidence: 90%

“…Nanda et al evaluated the XRCC-1 Arg194Trp SNP in HNSCC and reported enhanced ARIT to CRT in the patient with the polymorphic variant. 21 In head and neck cancers, on univariate and multivariate analysis, many studies have reported association of ARIT with patient characteristics (such as age, smoking, alcohol uptake status, performance status, gender, genetic predisposition, and nutritional status), carcinoma characteristics (tumor stage, nodal stage, and disease stage), and treatment characteristics (radiation dose, fraction size and scheme, volume of treatment, type of radiation, and chemotherapy administration). [46][47][48][49] In our study, on multivariate analysis, tumor stage (T3-T4) and nodal stage (N2-N3) were associated with dysphagia ARIT, age (> 50 years) with oral mucositis ARIT, and XRCC1 polymorphic variant (C/T + T/T) for oral mucositis and skin ARIT.…”

Section: Discussionmentioning

confidence: 99%

“…20 Nanda et al had not observed significant affiliation among treatment response and XRCC-1 Arg194Trp SNPs. 21 Studies were carried out to estimate the bio-predictive role of XRCC-1 SNPs for the clinical outcome of a lung, prostate, ovarian cancer, and HNSCC, but data regarding HNSCC are limited. [21][22][23][24][25] In this present study, we have studied XRCC-1 Arg194Trp polymorphism as a bio-predictor for ARIT in LALSCC undergoing CRT, and we hypothesize that patients with the polymorphic variant will have a higher ARIT and better response to CRT.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: To determine X-ray repair cross-complementing 1 gene (XRCC-1) Arg194Trp polymorphism as bio-predictor for clinical outcome in advanced laryngeal squamous cell carcinoma undergoing cisplatin-based chemoradiation (CRT). Methods: A total of 150 patients were enrolled in this prospective study.XRCC-1 Arg194Trp genotyping categorized patients as wild (C/C) and polymorphic (C/T or T/T). The primary endpoint was to assess acute radiationinduced toxicity (ARIT).Results: A significant correlation of skin (P-.04) and oral mucosal ARIT (P-.01) was noticed in the XRCC-1 polymorphic variant. A higher treatment response was noted in the polymorphic variant, and it shows a trend toward significance (P-.08). With 33 months of median follow-up, 2-year progression-free survival (PFS) and overall survival (OS) of wild vs polymorphic variant were 34.6% vs 46.9% (P-.066) and 50.6% vs 62.2% (P-.12).Conclusion: XRCC-1 polymorphic variants have significantly higher grade of >2 ARIT and may have improved trend for treatment response and PFS. K E Y W O R D Scisplatin-based chemoradiation, locally advanced laryngeal squamous cell cancer, polymerase chain reaction, single nucleotide polymorphism, X-ray repair cross-complementing 1 gene | INTRODUCTIONThe incidence rate of head and neck squamous cell cancer (HNSCC) worldwide is approximately 0.83 million cases per year. In India, HNSCC incidence is about 0.19 million cases per year. Laryngeal cancer is reported to be nearly 21% and 14% of all HNSCC worldwide and India. 1 Squamous cell carcinoma is the most commonly diagnosed variant in laryngeal cancer, and 40% of these cases present with advanced stage. 2 Laryngeal cancer has a composite etiology, and the risk is increased by factors such as alcohol drinking, smoking, and tobacco chewing, and the metabolites produced by these factors cause a surge in DNA strand interruption. 3,4

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some biomarkers have shown predictive value for outcomes with standard anticancer therapies, including platinum agents, cetuximab‐based chemotherapy, panitumumab‐based chemotherapy, afatinib, radiotherapy, concurrent chemoradiotherapy (CCRT), and immunotherapy . Such biomarkers are particularly important for clinical trial design, as they can aid in patient selection or stratification at randomization, serve as treatment‐monitoring tools, and help predict which specific patient groups are likely to derive the greatest benefit from a particular treatment.…”

Section: Prognostic and Predictive Biomarkersmentioning

confidence: 99%

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Hsieh

Wang

et al. 2019

Head & Neck

View full text Add to dashboard Cite

Background Biomarkers in head and neck squamous cell carcinoma (HNSCC) emerge rapidly in recent years, especially for new targeted therapies and immunotherapies. Methods Recent, relevant peer‐reviewed evidence were critically reviewed and summarized. Results This review article briefly introduces essential biomarker concepts, including purposes and classifications (predictive, prognostic, and diagnostic markers), and the phases of biomarker development. We summarize current biomarkers in order of clinical utility; p16 and human papillomavirus status remain the most important and validated biomarkers in HNSCC. The rationale for biomarker study design continues to evolve with technological advances, especially whole‐exome or whole‐genomic sequencing. Noninvasive body fluid and liquid biopsy biomarkers appear to hold strong potential for development as tools for early cancer detection, cancer diagnosis, monitoring of disease recurrence, and outcome prediction. In light of discrepancies among different technologies, standardized approaches are needed. Conclusion Biomarkers from cancer tissue or blood in HNSCC could direct new anticancer therapies.

show abstract

“…Subjects with low expression and/or activity of DNA repair enzymes have impaired ability to remove tobacco-induced DNA damage and are more likely to develop lung cancer. Excision repair cross complementing group 1 (ERCC1) and X-ray repair crosscomplementing group 1 (XRCC1) enzymes are needed to clear DNA damage and have been highlighted as potential biomarkers of clinical outcome in cancer [6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Gene-environment and gene-gene interactions between CHRNA3 rs1051730, XRCC1 rs25487, and ERCC1 rs735482 variants highly elevate the risk of lung cancer

Ezzeldin

El-Lebedy

Mohammed

2019

Egypt J Med Hum Genet

View full text Add to dashboard Cite

Background: Gene-gene and gene-environment interactions play an important role in cancer susceptibility. In this work, we studied the association of XRCC1 rs25487, ERCC1 rs735482, and CHRNA3 rs1051730 variants with lung cancer and assessed the modulatory effect of potential interaction between these variants on disease risk. Results: In this study, 86 primary lung cancer patients and 64 control subjects were genotyped for CHRNA3 rs1051730, XRCC1 rs25487, and ERCC1 rs735482 by real-time PCR. The frequency of the three studied variants was higher among lung cancer patients than in control subjects, but with no statistical significance. ERCC1 rs735482 variant was associated with 6.9-fold increased risk to develop lung cancer among smokers (p = 0.03). Concomitant presence of CHRNA3 and ERCC1 wild alleles was associated with 2.7-fold elevated risk of lung cancer (p < 0.0001), while concomitant presence of CHRNA3 rs1051730 variant allele with ERCC1 wild allele was associated with 20-fold elevated risk (p < 0.000). Concomitant presence of both variants, ERCC1 rs735482 and CHRNA3 rs1051730, was associated with 9.9-fold elevated risk (p < 0.0001). Meanwhile, the concomitant presence of XRCC1 rs25487 with either ERCC1 rs735482 or CHRNA3 rs1051730 or both was not associated with increased risk of the disease. Conclusion: Our results emphasize the role of gene-gene interaction in the pathogenesis of lung cancer. Largescale further studies to clarify the underlying mechanisms are needed.

show abstract

Evaluation of XRCC1 Gene Polymorphism as a Biomarker in Head and Neck Cancer Patients Undergoing Chemoradiation Therapy

Cited by 32 publications

References 36 publications

Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation

Prospective evaluation of XRCC‐1 Arg194Trp polymorphism as bio‐predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin‐based chemoradiation

Review of emerging biomarkers in head and neck squamous cell carcinoma in the era of immunotherapy and targeted therapy

Gene-environment and gene-gene interactions between CHRNA3 rs1051730, XRCC1 rs25487, and ERCC1 rs735482 variants highly elevate the risk of lung cancer

Contact Info

Product

Resources

About